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Abstract 
Like many other neurodegenerative diseases, age is a major risk factor in the 
development of ALS/FTD. But why is this the case? Recent genetic advances have 
highlighted some of pathways involved in the development of disease, and, 
strikingly, they appear to substantially overlap with those known to directly modulate 
the ageing process. Many ALS/FTD linked genes play a direct role in 
autophagy/lysosomal degradation, one of most important pathways linked to ageing. 
However, systemic processes such as inflammation, as well as cellular maintenance 
pathways including RNA splicing and nuclear-cytoplasmic transport have been 
increasingly linked both to disease and ageing. We highlight some of the shared 
mechanisms between the ageing process itself and emerging pathogenic 
mechanisms in ALS/FTD. 
 
Introduction 
Frontotemporal dementia (FTD) comprises a diverse array of disorders broadly 
characterized by the progressive degeneration of the frontal and temporal lobes [1]. FTD is 
the second most common cause of early onset dementia after Alzheimer’s disease [2, 3] and 
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is strongly heritable, with 30%-50% of patients displaying a strong family history [4]. FTD can 
be clinically categorized either by behavioural symptoms (behavioural variant FTD, bvFTD, 
the most heritable form) or by language dysfunction (primary progressive aphasia, PPA) [5, 
6] At the pathological level FTD is characterized by an accumulation of proteinaceous 
inclusions in the brain, with each pathological subtype defined as frontotemporal lobar 
degeneration (FTLD) followed by the specific inclusion identified. Inclusions in the majority of 
FTD patient brains contain either tau protein (FTLD-Tau) or TDP-43 (FTLD-TDP). However, 
about 10% of FTD patients present with FUS inclusions (FTLD-FUS) and some have poly-
ubiquitinated inclusions with none of these proteins (FTD-UPS), or no inclusions at all (FTD-
ni) [7]. The clinical symptoms of FTD appear to be determined by the pattern of brain 
atrophy rather than by the molecular identity of the inclusions [8].  
 
Although clinically distinct in their pure forms, FTD is genetically and pathologically related to 
amyotrophic lateral sclerosis (ALS), a motor neuron disease that causes upper and lower 
motor neuron degeneration, eventually leading to paralysis and death by respiratory failure. 
The link between FTD and ALS has been long known [9, 10], yet only recently was it 
discovered that several mutations can cause either of these diseases [11] and in about 15% 
of cases (both familial and sporadic) patients develop both diseases [12, 13]. FTD and ALS 
also overlap pathologically, as nearly all sporadic forms of ALS (sALS) and nearly 90% of 
familiar ALS (fALS) are associated with TDP-43 inclusions, with the exception of fALS 
caused by SOD1 and FUS mutations, which are characterized by SOD1- or FUS-containing 
inclusions respectively [14-16]. 
 
The similarities between FTD and ALS suggest that these are two forms of the same 
disease spectrum. However, unlike FTD, ALS is mostly a sporadic disease [17]. It is a 
complex polygenic trait with approximately 10-20% common SNP-based heritability [18, 19], 
which is significantly lower than, for instance, Alzheimer’s disease [20]. Low-frequency 
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genetic variants play a major role in heritability of ALS, and many of them are not yet 
identified [18].  
 
Ageing is the main risk factor for both FTD and ALS (Fig 1) [21, 22]. The incidence of ALS 
increases dramatically with age [23] [21] and, of the 5% of patients who develop ALS under 
the age of 30 [23], most carry specific mutations such as FUS and SOD1 [23]. Similarly, the 
age of onset of FTD is usually above 35, with incidence increasing considerably with age 
[22, 24]. In this review, we explore the links between the ageing process and the 
development of FTD/ALS. We discuss how the pathogenic mechanisms of ALS and FTD are 
closely related to pathways affecting the ageing process itself. We exemplify this with some 
key molecular mechanisms underlying ALS and FTD, uncovered by the expanding list of 
genes associated with these diseases, and discuss the roles of these pathways in the 
ageing process. The overlap between the molecular mechanisms leading to both ageing and 
FTD/ALS may well explain why advancing age has such an important function in disease 
development.  
 
Overlapping mechanisms in ageing and FTD/ALS 
The ageing process was once thought to result from random accumulation of insults to 
molecules, cells, tissues and the systemic environment due to the passage of time, and 
therefore intractable for both experimental analysis and medical intervention, However, in 
the last 30 years, a number of conserved mechanisms have been shown to modulate 
ageing, with single genetic mutations and dietary or pharmacological interventions able to 
extend the lifespan across a variety of species [25]. We discuss four key process which 
become dysregulated during ageing and have also been implicated in the aetiology 
of FTD/ALS by genetic studies: autophagy, inflammation, nuclear-cytoplasmic 
transport and splicing of RNA (Table 1). 
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Autophagy 
Autophagy plays an important role in the ageing process [26]. Mitotic cells can dilute out 
defective proteins and organelles by cell division and biosynthesis. However, as neurons are 
mostly post-mitotic cells, efficient mechanisms for clearing proteins and organelles are 
critical to maintain neuronal homeostasis [27]. Protein homeostasis is maintained by the 
ubiquitin (Ub)-proteasome system (UPS) and autophagy, both of which clear defective 
cytoplasmic components. The UPS targets mis-folded proteins tagged with ubiquitin to the 
proteasome, while autophagy delivers cytoplasmic components to lysosomes. There are 
three types of autophagy: macro, micro and chaperone-mediated autophagy. 
Macroautophagy (hereafter referred to as autophagy), is the process by which 
autophagosomes engulf proteins or organelles and eventually fuse with lysosomes, leading 
to degradation of their cargoes [27] (Fig 2). Specific adaptors, such as sequestosome-1 
(p62/SQSTM-1), sequester poly-ubiquitinated aggregates into autophagosomes. Over the 
past decade, growing evidence has revealed an important relationship between autophagy 
and lifespan. Advancing age causes a progressive impairment of the UPS and autophagy, 
particularly in neurons [27]. These age-related defects may be due to impaired activity of key 
components of these pathways, because experimentally restored activity of these can lead 
to improved cellular homeostasis and organ function [28]. Moreover, lifespan-extending 
interventions often induce and require autophagy [26], and over-expression of autophagy 
pathway components, such as Atg8 [29], in Drosophila brains, or Atg5 in mice [30], is 
sufficient to extend lifespan. Autophagy is therefore a conserved pathway which modulates 
the ageing process. It is also a highly relevant pathway in the development of a number of 
neurodegenerative diseases, including FTD/ALS [31].  
 
Several mutations associated with ALS and FTD are in genes involved in autophagy, 
including Ubiquilin 2 (UBQLN2), p62/SQSTM1, optineurin (OPTN) and valosin-containing 
protein (VCP) (see Fig 2). p62/SQSTM1, OPTN and UBQLN2 are adaptor proteins that 
target poly-ubiquitinated substrates for degradation by delivering them to the 
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autophagosomal membrane protein LC3 [32]. ALS/FTD causing mutations occur throughout 
the coding regions of p62/SQSTM1 [33, 34] and reduce p62/SQSTM1 binding to LC3 [35]. 
Risk mutations in UBQLN2 [36, 37] most commonly alter a conserved proline residue, 
affecting its co-localisation with OPTN on endosomal vesicles [38] and impair both 
autophagic and proteasomal mediated degradation of mis-folded and aggregated proteins  
[36, 39, 40]. An OPTN E478G mutation disrupts the delivery of damaged substrates, such as 
mitochondria, to autophagosomes [41]. Further cementing the link between this pathway and 
FTD/ALS was the discovery of mutations in Tank Binding Kinase 1 (TBK1) [42]. TBK1 
directly phosphorylates and binds to p62 and OPTN [42-44], and loss of these interactions 
also impairs delivery of damaged mitochondria to autophagosomes [44, 45]. Moreover, most 
TBK1 mutations associated to ALS and FTD are missense [46] or abolish binding to OPTN 
[42][47], indicating these are loss of function mutations that would impair this pathway. 
Intriguingly, disease-linked mutations in VCP, an AAA(+)-ATPase chaperone-like protein can 
affect both autophagosome maturation [48, 49] and induce mitochondrial defects [50, 51]. 
 
 Interestingly, genes that are solely associated to FTD, rather than to both FTD and ALS 
appear to affect lysosomal function directly. FTD-linked mutations in Charged Multivesicular 
Body Protein 2B (CHMP2B) and progranulin (GRN), a secretory lysosomal protein that 
regulates lysosomal function and biogenesis [52], cause defects in lysosomal storage [53, 
54]. Moreover, two FTD risk loci, Transmembrane Protein 106B (TMEM106B) and cathepsin 
D, are also involved in modulating lysosomal function [54][55]. Thus, while genes associated 
with both ALS and FTD seem to be involved in the early steps of autophagy, during poly-
ubiquitinated protein delivery to the autophagosome, those genes linked exclusively to FTD 
appear to function at later steps in the autophagy process, during lysosomal maturation 
and/or function [56].  
 
Therefore several lines of evidence link both aging and FTD/ALS to autophagy and 
lysosomal degradation. One inference from this is that interventions which promote 
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autophagy and extend lifespan may also be beneficial for FTD/ALS. Notably, increasing 
autophagy can indeed alleviate symptoms in ALS/FTD models. For instance, feeding 
rapamycin, an autophagy enhancer which also extends lifespan in flies and mice [57, 58], to 
a TDP-43 mouse or fly model ameliorated symptoms and reduced TDP-43 aggregation [59, 
60]. 
 
Inflammation 
A major feature of advancing age is a gradual, chronic increase in pro-inflammatory status, a 
phenomenon named “inflamm-aging” [61]. How and why this increase happens is still a 
matter of debate [62]. In the brain, age-related inflammation is mostly driven by an increase 
in inflammatory microglia, the resident immune cells for the brain [63]. Reducing IKKß, a key 
mediator of the immunity pathway, in hypothalamic microglia in mice can improve health and 
extend lifespan [64], suggesting that brain inflammation is a key driver of the ageing 
process. An almost ubiquitous feature of neurodegenerative diseases is neuroinflammation: 
in response to damage in neurons, microglia are activated to clear cellular debris and help 
neuronal repair, but prolonged activation can also contribute to neuronal damage [65]. 
 
Several genes associated with ALS/FTD are directly linked to inflammatory pathways, 
suggesting that neuroinflammation is not merely a defensive physiological response in 
neurons already damaged by disease, but rather that inflammation can also directly 
contribute to pathogenesis. Mice carrying mutations in SOD1, the first gene to be associated 
with ALS, show astrogliosis and microglial activation [66]. Moreover, mutant SOD1 
expression in astrocytes and microglia accelerate disease development [67, 68]. 
Conversely, pharmacological or genetic reduction of inflammation in SOD1 mutant animals 
ameliorates pathology [69, 70]. Mice expressing mutant CHMP2B or deficient for GRN have 
pro-inflammatory phenotypes accompanied by microglial proliferation [71-73] and FTD 
patients carrying GRN mutations display a distinctive pro-inflammatory CSF profile [74]. 
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Interestingly, a recent GWAS study investigating the genetic basis for the rate of aging in the 
cerebral cortex, identified FTD related alleles of GRN and TMEM106B as responsible for 
higher rates of age-related changes in transcription [75]. In particular, the TMEM106B FTD 
risk allele is associated with an increased age-related, microglia-specific, inflammatory 
profile, even in a healthy brain [75]. Another autophagy-related gene, TBK1, is activated by 
several immune effectors, such as Toll-like receptors, thereby inducing the release of type I 
interferon (IFN) and proinflammatory cytokines [47]. Moreover, TBK1 alleles linked to 
FTD/ALS can display reduced IFN induction [47]. However, whether they affect immune 
function in neurodegenerative disease context remains to be seen. That these 
autophagy/lysosomal degradation genes are also implicated in microglial function raises the 
possibility that microglial-mediated protein or aggregate degradation plays a role in disease 
pathogenesis. 
 
 An innate immune receptor recently implicated in FTD/ALS, TREM2, is expressed by 
microglia and plays a key role in inflammation and phagocytosis. TREM2 mutations have 
been linked to a number of neurodegenerative diseases, including FTD and ALS. TREM2 
missense mutations linked to FTD reduce protein shedding causing a reduction in soluble 
TREM2, (sTREM2) inflammatory CSF profiles and impaired phagocytosis [76]. However, a 
decrease in sTREM2 is also found in FTD patients who do not carry this mutation, 
suggesting that TREM2 may play a broader role in FTD [76]. Overall therefore, inflammation 
is part of disease progression in ALS and FTD. A number of causal genes are involved in 
inflammatory response and, in the case of GRN and TMEM106B, also in ageing related 
inflammatory increase, suggesting again a link between the ageing process and disease 
development. 
 
Nuclear-cytoplasmic transport 
Proteins and RNA transcripts shuttle between the nucleus and the cytoplasm via the nuclear 
pore complex (NPC). Transport across this large, multi-protein channel is achieved by 
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nuclear transport receptors (NTR) powered by a RanGTP gradient [77]. The NPC is a highly 
stable structure, with very low turnover of scaffold proteins [78] [79]. NPC proteins are 
therefore extremely vulnerable to age-related damage, particularly in post-mitotic cells such 
as neurons. Moreover, the expression of some essential NPC components, such as Nup93 
[80], decreases during ageing, resulting in leakage of cytoplasmic contents into the nucleus 
[78]. Notably, in yeast modulation of NPC proteins or NTRs can increase lifespan, 
suggesting that the NPC plays a direct role in ageing [81, 82].  
 
Recent evidence suggests that nuclear transport defects may promote FTD/ALS 
development [83]. C9orf72 hexanucleotide expansion (C9) is the most common genetic 
cause of ALS and FTD, accounting for 30-40% and 10% of familial and sporadic disease, 
respectively [84]. ALS/FTD patients can carry thousands of copies of this GGGGCC stretch 
in the first intron of C9orf72, whereas healthy individuals carry fewer than 30 copies [85, 86]. 
C9 is transcribed into a repetitive and stable RNA structure that produces highly toxic 
dipeptide-repeat proteins [87]. Four independent studies using C9orf72 hexanucleotide 
expansion (C9) models demonstrated that nucleocytoplasmic defects were key mediators of 
the pathology [88-91]. Furthermore, in yeast and Drosophila, modulating the expression 
levels of NPC or export components rescues C9 toxicity [88-91], highlighting the importance 
of impaired nuclear-cytoplasmic transport as a toxic mechanism. Defects in nuclear-
cytoplasmic transport can lead to TDP-43 mis-localisation from the nucleus to the cytoplasm 
[92], a typical feature of C9 patients but also of ALS/FTD more generally, since the 
accumulation of insoluble cytoplasmic TDP-43 or FUS aggregates is concomitant with 
nuclear depletion of these proteins. TDP-43 and FUS are predominantly nuclear RNA-
binding proteins involved in transcription, translation and splicing. Mutations in the nuclear 
localization signal (NLS) of FUS cause the most aggressive phenotypes and a mutation 
totally truncating the NLS of FUS leads to juvenile disease onset [93], indicating that mis-
localization is critical for disease development. Mutations in the NLS of TDP-43 have not 
been identified. However, nuclear depletion of this protein is observed in FTD/ALS patients, 
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suggesting an impairment in nuclear-cytoplasmic transport. Impairments in nuclear-
cytoplasmic transport due to imbalance in levels of importins are also seen in FTD-TDP-43, 
ALS-SOD1 and sporadic ALS patients [92] [94]. TDP-43 nuclear depletion in patient cells 
likely causes down-regulation of TDP-43 target mRNAs [95, 96].  
 
Similarly to TDP-43 in FTD/ALS, several proteins specifically associated with ALS, such as 
EWS [97, 98], TAF15 [97] hnRNPA2B1 and hnRNPA1 [99], are predominantly nuclear RNA-
binding proteins and components of stress granules that are depleted from the nucleus in 
patient cells. Moreover, mutations in GLE1, a direct regulator of nuclear-cytoplasmic 
transport that is also implicated in stress granule formation, can cause ALS [100]. 
Interestingly, these disease causing mutations also seem to lead to cytoplasmic localisation 
[101], suggesting  a general mechanism of toxicity whereby proteins with mostly nuclear 
functions are relocalised to the cytoplasm, possibly altering stress granule formation and 
mRNA metabolism. Therefore altered nucleocytoplasmic transport may contribute towards 
the mis-localisation of nuclear proteins observed in FTD/ALS and this could be exacerbated 
by age-related decline in NPC function. 
 
Splicing 
Correct splicing of RNA is impaired during normal ageing. An increase in the expression of 
genes involved in RNA processing increases alternative splicing in ageing mice [102]. In 
human brains, the expression levels of several splicing regulators change with age, and an 
age-dependent increase in splicing has been associated with augmented activity of 
Polypyrimidine tract-binding protein 1 (PTBP1) [103], these aberrant splicing events could 
lead to the production of non-functional proteins, and are associated with disease-linked 
genes or genes involved in DNA repair. Recent reports also suggest that splicing plays an 
active role in ageing. For instance, a study on mice with accelerated ageing due to progeria 
mutations showed that the number of alternatively spliced genes increases with age [102]. In 
C. elegans, splicing factor 1 (SPA1) is required for lifespan extension by several 
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interventions [104] and, more importantly, SPA1 up-regulation was sufficient to extend 
lifespan.  
 
A direct consequence of the relocation of nuclear factors to the cytoplasm is loss of nuclear 
function. Depletion of TDP-43 causes splicing changes, including increased cryptic exon 
incorporation into transcripts, which are also detected in brain tissue from ALS/FTD patients 
[95] [105, 106]. Other genes implicated in ALS also appear to cause mis-splicing, for 
instance, depletion of FUS in mice causes splicing defects [96, 107], which is consistent with 
the RNA-binding function of FUS near repressed exons during spicing. Similarly, ALS-linked 
hnRNPA2B1 deletions have been associated with splicing defects in patient cells [108]. 
Therefore increasing evidence indicates that splicing is a modulator of ageing and is directly 
associated to ALS and FTD development. These findings further support the tight 
relationship between the ageing process and ALS/FTD disease progression. 
 
 
Conclusions 
A number of FTD/ALS genes are implicated in ageing pathways (Table 1). This substantial 
overlap could explain why ageing is the main risk factor for these diseases. Recent models 
propose that ALS is a multi-step process [109] and ageing may facilitate some aspects of 
the development of this disease. For instance, sub-threshold defects in these pathways may 
be pushed into overt dysfunction during aging. As familial forms of the disease develop 10 
years earlier than sporadic forms [110], it is plausible that genetic mutations further lower the 
threshold by which  the ALS pathogenic process can be driven by ageing. This opens the 
possibility of re-purposing drugs known to affect lifespan as possible therapeutic avenues. 
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Gene Symbol Name Pathway 
ALS or 
FTD 
OPTN Optineurin Autophagy ALS/FTD 
VCP 
Valosin Containing 
Protein 
Autophagy/Mitochondrial 
function 
ALS/FTD 
UBQLN2 Ubiquilin 2 Autophagy/Proteasome ALS/FTD 
SQSTM1 Sequestosome 1 Autophagy ALS/FTD 
TBK1 TANK Binding Kinase 1 Autophagy/Inflammation ALS 
GRN Progranulin 
Lysosomal degradation 
/inflammation 
FTD 
CHMP2B 
Charged Multivesicular 
Body Protein 2B 
Lysosomal 
degradation/inflammation 
FTD 
SOD1 Superoxide dismutase Inflammation ALS 
TREM2 
Triggering Receptor 
Expressed On Myeloid 
Cells 2 
Inflammation FTD 
FUS 
FUS RNA binding 
protein 
Nucleocytoplasmic 
transport/splicing 
ALS 
TARDBP 
TAR DNA Binding 
Protein 
Nucleocytoplasmic transport/ 
splicing 
ALS 
TAF15 
TATA-Box Binding 
Protein Associated 
Factor 15 
Nucleocytoplasmic 
transport/RNA metabolism 
ALS 
C9orf72 
C9orf72 hexanucleotide 
repeat expansion  
Nucleocytoplasmic 
transport/splicing 
ALS/FTD 
HNRNPA2B1 
Heterogeneous Nuclear 
Ribonucleoprotein A2/B1 
Nucleocytoplasmic 
transport/splicing 
ALS/FTD 
HNRNPA1 
Heterogeneous Nuclear 
Ribonucleoprotein A1 
Nucleocytoplasmic transport/ 
splicing 
ALS/FTD 
GLE1 
GLE1, RNA Export 
Mediator 
Nucleocytoplasmic transport ALS 
TMEM106B 
Transmembrane Protein 
106B 
Autophagy/Inflammation FTD 
 
Table 1. Genetic causes and risk factors for ALS/FTD implicated in ageing pathways 
List of genes discussed in the main text implicated in the development of ALS/FTD and 
associated ageing pathways they appear to be involved in. 
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Figure1. Incidence of FTD and ALS increase with age. A. Incidence of ALS in the UK, 
according to the 1990-2005 in the General Practice Research Database (Data kindly 
supplied by Alvaro Alonso) [21]. B. Incidence of FTD in Sweden according to the Swedish 
Dementia Registry [22].   
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Figure 2. The autophagy pathway and ALS/FTD genes. The autophagy process is 
initiated by the phosphorylation of ULK1, this activates the pre-initiation complex which in 
turn phosophorylates the PI3K CII complex allowing it to catalyse the first steps required to 
generate an elongating double membrane. A number of components participate in the 
elongation reaction, leading to the binding of Atg12/Atg5/Atg16L complex and LC3 II to the 
membrane, which leads to the membrane enclosing a portion of the cytosol. As the 
membrane is closing misfolded proteins and damaged organelles are targeted to the 
autophagosome, which then fuses with a late endosome or lysosome generating an 
autolysosome where the organelles are digested. Autophagic receptors (p62, OPTN) and 
adaptor proteins confer selectivity by tethering specific cargoes, such as poly-ubiquitinated 
proteins or mitochondria to LC3 in forming phagophores, thus targeting them for 
degradation. Several FTD/ALS linked genes are implicated at different stages of this 
pathway. 
 
 
